Novel Dicarboximide BK124.1 Breaks Multidrug Resistance and Shows Anticancer Efficacy in Chronic Myeloid Leukemia Preclinical Models and Patients’ CD34<sup>+</sup>/CD38<sup>−</sup> Leukemia Stem Cells

Novel Dicarboximide BK124.1 Breaks Multidrug Resistance and Shows Anticancer Efficacy in Chronic Myeloid Leukemia Preclinical Models and Patients’ CD34<sup>+</sup>/CD38<sup>−</sup> Leukemia Stem Cells

The search is ongoing for new anticancer therapeutics that would overcome resistance to chemotherapy. This includes chronic myeloid leukemia, particularly suitable for the studies of novel anticancer compounds due to its homogenous and well-known genetic background. Here we show anticancer efficacy...

Full description

Bibliographic Details
Main Authors: Iga Stukan, Marek Gryzik, Grażyna Hoser, Andrew Want, Wioleta Grabowska-Pyrzewicz, Mikolaj Zdioruk, Mariola Napiórkowska, Marcin Cieślak, Karolina Królewska-Golińska, Barbara Nawrot, Grzegorz Basak, Urszula Wojda
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Cancers
Subjects:
chemotherapy
multidrug resistance
MDR1
P-glycoprotein
leukemia stem cells
chronic myeloid leukemia
Online Access:https://www.mdpi.com/2072-6694/14/15/3641

Internet

https://www.mdpi.com/2072-6694/14/15/3641

Similar Items